SABS - SAB Biotherapeutics Inc
IEX Last Trade
2.9
0 0%
Share volume: 5,492
Last Updated: Fri 30 Aug 2024 09:57:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.90
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-10 | 2022-11-14 | 2023-04-14 | 2023-05-15 | 2023-08-21 | 2023-11-13 | 2024-03-29 | 2024-05-20 | |
| Assets | |||||||||
| Total Assets | 59.155 M | 52.507 M | 50.905 M | 42.672 M | 35.443 M | 28.336 M | 83.941 M | 71.371 M | |
| Current Assets | 27.751 M | 22.182 M | 22.097 M | 15.032 M | 9.006 M | 3.128 M | 58.907 M | 46.951 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.521 M | 907.865 K | 1.494 M | 1.209 M | 867.604 K | 702.231 K | 2.341 M | 2.701 M | |
| Short Term Investments | 1.521 M | 907.865 K | 1.494 M | 1.209 M | 867.604 K | 702.231 K | 2.341 M | 2.701 M | |
| Total Receivables | 9.613 M | 12.942 M | 5.557 M | 763.123 K | 364.117 K | 0.000 | 0.000 | 193.232 K | |
| Current Cash | 16.616 M | 8.332 M | 15.047 M | 13.060 M | 7.774 M | 2.425 M | 56.566 M | 44.057 M | |
| Total Non-current Assets | 31.404 M | 30.325 M | 28.807 M | 27.640 M | 26.436 M | 25.209 M | 25.034 M | 24.420 M | |
| Property Plant Equipment | 24.837 M | 24.032 M | 23.251 M | 22.374 M | 21.528 M | 20.622 M | 19.737 M | 17.903 M | |
| Other Assets | 6.567 M | 6.293 M | 5.557 M | 5.266 M | 4.909 M | 4.587 M | 5.298 M | 5.282 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 59.155 M | 52.507 M | 50.905 M | 42.672 M | 35.443 M | 28.336 M | 83.941 M | 71.371 M | |
| Total liabilities | 22.034 M | 21.884 M | 19.847 M | 18.269 M | 15.726 M | 13.080 M | 26.642 M | 18.549 M | |
| Total current liabilities | 16.137 M | 17.101 M | 14.993 M | 13.666 M | 11.011 M | 9.211 M | 10.813 M | 8.305 M | |
| Accounts Payable | 4.944 M | 5.484 M | 3.679 M | 1.445 M | 1.404 M | 1.083 M | 945.927 K | 1.240 M | |
| Other liabilities | 1.140 M | 357.516 K | 320.930 K | 238.344 K | 595.860 K | 417.102 K | 11.774 M | 6.306 M | |
| Current long term debt | 1.335 M | 1.379 M | 1.396 M | 1.095 M | 784.880 K | 1.200 M | 1.853 M | 1.513 M | |
| Long term debt | 4.756 M | 4.425 M | 4.533 M | 4.365 M | 4.119 M | 3.452 M | 4.054 M | 3.938 M | |
| Other liabilities | 1.140 M | 357.516 K | 320.930 K | 238.344 K | 595.860 K | 417.102 K | 11.774 M | 6.306 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 37.121 M | 30.623 M | 31.058 M | 24.403 M | 19.716 M | 15.256 M | 57.299 M | 52.822 M | |
| Common stock | 42.999 M | 43.031 M | 44.956 M | 50.397 M | 50.421 M | 52.406 M | 6.764 M | 9.242 M | |
| Retained earnings | -32.919 M | -39.995 M | -47.870 M | -55.224 M | -62.104 M | -67.207 M | -90.064 M | -95.089 M |